Phase II Trial of Cadonilimab(PD-1/CTLA-4) Combination Regimen Launches in the United States for Perioperative Treatment of Gastric Cancer

Phase 2CadonilimabPositive

AI Analysis

Summary

Akeso announced the launch of a Phase II clinical trial in collaboration with Memorial Sloan Kettering Cancer Center to evaluate cadonilimab, a PD-1/CTLA-4 combination regimen, for perioperative treatment of gastric cancer in the United States.

Clinical Trial Data

Phase

Importance:5/10

Sentiment:

0.50

Phase 2Immuno-oncologyGastric cancerPD-1/CTLA-4 combinationClinical trialPartnership

Related Companies

$UTHR

Read the original article

Published by PR Newswire Biotech on July 14, 2026 8:18 AM

Read Original